Source Paper
V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats
R Landgraf, R Gerstberger, A Montkowski, JC Probst, CT Wotjak et al.
Source Paper
R Landgraf, R Gerstberger, A Montkowski, JC Probst, CT Wotjak et al.
Journal of Neuroscience • 1995
To develop and validate a vasopressin (AVP) receptor knockdown strategy, we infused an antisense oligodeoxynucleotide to the V1 subtype mRNA into the septum of male rats with osmotic minipumps and measured behavioral, cellular and molecular parameters. Compared to vehicle and scrambled-sequence oligo controls, chronic antisense administration for up to 4 d diminished the ability of the animals to distinguish a previously exposed juvenile from a novel one and to respond to exogenous AVP (1 ng/5 microliters, intracerebroventricular) with an improved social memory. Furthermore, anxiety-related behavior was reduced. As measured in the behaviorally tested rats, antisense treatment resulted in a reduced binding of radiolabeled AVP in the septum, but not in other limbic brain areas (receptor autoradiography), and an increased amount of V1 receptor mRNA (reverse transcriptase PCR), indicating translational arrest and ongoing transcriptional activity. In sense oligo-treated rats, on the other hand, both the social and the anxiety-related behavior scores lay between levels obtained in control and antisense-treated animals. These sense-treated rats showed a slightly reduced V1 receptor density in the septum and reduced receptor mRNA levels, indicating hybridization of the sense oligo to the DNA. The data show the potential of antisense targeting to further reveal relationships between local gene expression, neuropeptide-receptor interactions in distinct brain areas, and behavioral performance.
Objective: Assessment of the ability to distinguish a previously exposed juvenile from a novel one in rats
This is a Social Discrimination Test protocol using rat as the model organism. The procedure involves 8 procedural steps, 1 equipment items, 5 materials. Extracted from a 1995 paper published in Journal of Neuroscience.
Model and subjects
rat • Not specified • male • Not specified • Not specified
Study window
~4 day study window
Core workflow
Surgical implantation of osmotic minipumps • Chronic infusion period • Social discrimination test - exposure phase
Primary readouts
Key equipment and reagents
Verified items
0
Direct vendor links
0
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
Use the page like this
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Implant osmotic minipumps containing antisense oligodeoxynucleotide, scrambled-sequence oligo, or vehicle into the septum of male rats
Note: Three treatment groups: antisense, scrambled-sequence control, and vehicle control
“infused an antisense oligodeoxynucleotide to the V1 subtype mRNA into the septum of male rats with osmotic minipumps”
Allow chronic antisense administration to proceed for up to 4 days
Note: Behavioral testing occurs during this period
“chronic antisense administration for up to 4 d diminished the ability of the animals to distinguish a previously exposed juvenile from a novel one”
Expose test rat to a previously encountered juvenile rat to establish familiarity
Note: This juvenile becomes the 'familiar' stimulus animal
“ability of the animals to distinguish a previously exposed juvenile from a novel one”
Present test rat with both the previously exposed (familiar) juvenile and a novel juvenile rat simultaneously or sequentially to assess discrimination ability
Note: Measure ability to distinguish between familiar and novel juveniles
“ability of the animals to distinguish a previously exposed juvenile from a novel one”
Administer exogenous vasopressin intracerebroventricularly to assess response to AVP treatment
Note: Dose: 1 ng/5 microliters; measure if AVP improves social memory
“respond to exogenous AVP (1 ng/5 microliters, intracerebroventricular) with an improved social memory”
Measure anxiety-related behavior in treated and control animals
Note: Antisense treatment resulted in reduced anxiety-related behavior
“anxiety-related behavior was reduced”
Perform receptor autoradiography using radiolabeled AVP to measure V1 receptor binding in septum and other limbic brain areas
Note: Conducted on behaviorally tested rats; measures binding in septum and other limbic regions
“As measured in the behaviorally tested rats, antisense treatment resulted in a reduced binding of radiolabeled AVP in the septum, but not in other limbic brain areas (receptor autoradiography)”
Perform reverse transcriptase PCR to measure V1 receptor mRNA levels in treated animals
Note: Antisense treatment resulted in increased V1 receptor mRNA, indicating translational arrest
“increased amount of V1 receptor mRNA (reverse transcriptase PCR), indicating translational arrest and ongoing transcriptional activity”
This section explains what the experiment is doing, which readouts matter, what the data artifacts usually look like, and how the analysis should flow from raw capture to reported result.
Assessment of the ability to distinguish a previously exposed juvenile from a novel one in rats
Objective
Assessment of the ability to distinguish a previously exposed juvenile from a novel one in rats
Subjects
From paperrat • Not specified • male • Not specified • Not specified
Cohort notes
From paperJuvenile rats used as stimulus animals for social discrimination testing
Surgical implantation of osmotic minipumps (Not specified)
Chronic infusion period (up to 4 days)
Social discrimination test - exposure phase (Not specified)
Social discrimination test - discrimination phase (Not specified)
Ability to distinguish previously exposed juvenile from novel juvenile
From paperBehavioral scores compared between antisense-treated, scrambled oligo-treated, and vehicle control groups.
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
Response to exogenous AVP with improved social memory
From paperBehavioral scores compared between antisense-treated, scrambled oligo-treated, and vehicle control groups.
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
Anxiety-related behavior scores
From paperBehavioral scores compared between antisense-treated, scrambled oligo-treated, and vehicle control groups.
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
Radiolabeled AVP binding in septum
From paperBehavioral scores compared between antisense-treated, scrambled oligo-treated, and vehicle control groups.
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
Ability to distinguish previously exposed juvenile from novel juvenile
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
Response to exogenous AVP with improved social memory
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
Anxiety-related behavior scores
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
Radiolabeled AVP binding in septum
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
Acquisition
Collect raw experimental outputs with enough metadata to preserve sample identity, condition, and timing.
Preprocessing / cleaning
Behavioral scores compared between antisense-treated, scrambled oligo-treated, and vehicle control groups.
Scoring or quantification
Quantify the primary readouts for this experiment: Ability to distinguish previously exposed juvenile from novel juvenile; Response to exogenous AVP with improved social memory; Anxiety-related behavior scores; Radiolabeled AVP binding in septum.
Statistical comparison
Statistical method not yet structured for this page.
Reporting output
Report representative outputs alongside summary comparisons for Ability to distinguish previously exposed juvenile from novel juvenile, Response to exogenous AVP with improved social memory, Anxiety-related behavior scores, Radiolabeled AVP binding in septum.
Source links and direct wording from the methods section for validation and deeper review.
Citation
R Landgraf et al. (1995). V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. Journal of Neuroscience
“”
“”
“”
“”
Direct vendor pages are linked from the protocol above. This section stays focused on the full comparison view and the prep checklist.
Gather these items before starting the experiment. Check off items as you prepare.
Not specified • Not mentioned • Not mentioned • Not mentioned
Not specified • Not mentioned • Not mentioned • Not mentioned
Not specified • Not mentioned • Not mentioned • Not mentioned
Not specified • Not mentioned • Not mentioned • Not mentioned
Not specified • Not mentioned • Not mentioned • Not mentioned
Not specified • Not mentioned • Not mentioned • Not mentioned
Not specified • Not mentioned
Use this section as the page quality checkpoint. It keeps section navigation, evidence access, readiness, and verification meaning in one place.
Current status surfaces were computed from experiment data updated Feb 28, 2026.
Source access
Jump back into the original paper or the methods evidence section when you need exact wording, exclusions, or method-specific caveats.
This protocol has structured steps plus evidence quotes, and is ready for canonical sync.
Steps
8
Evidence Quotes
14
Protocol Items
6
Linked Products
0
Canonical Sync
Pending
What this means
The completeness score reflects how much structured protocol data is present: steps, methods evidence, listed materials, linked products, and paper provenance.
Computed from the current experiment record updated Feb 28, 2026.
Canonical Sync shows whether a ConductGraph-backed protocol is available for this experiment route right now. It is a sync-status signal, not a claim that every downstream vendor link or step detail is perfect.
Steps
8
Evidence
14
Specific Products
0/0
Canonical Sync
Pending
What this score means
The verification score reflects evidence coverage, subject detail, paper provenance, step depth, and whether linked products resolve to specific item pages instead of generic searches.
Computed from the current experiment record updated Feb 28, 2026.
A page can have structured steps and still need review when evidence is thin, product links are generic, or canonical protocol coverage is still pending.
What still needs work